Exelixis Begins Phase II Study for Cancer Drug
Posted on: Friday, 22 December 2006, 09:00 CST
Exelixis has commenced a phase II clinical trial of its oncology drug candidate XL880 in patients with gastric cancer following a previous study into the drug's effects on papillary renal cell carcinoma.
XL880 is an orally bioavailable small molecule inhibitor of the MET and VEGF receptor tyrosine kinases that are involved in tumor cell growth, migration, and angiogenesis. The multi-center open-label phase II study will be conducted at multiple clinical sites and enroll patients with metastatic, poorly differentiated diffuse gastric cancer, a tumor type that is associated with amplification of the MET gene.
The primary objectives of the study are to determine best-confirmed response rate and to evaluate safety and tolerability of XL880 administered orally for five consecutive days every two weeks. Secondary objectives are to assess progression-free survival, overall survival, duration of response, and to continue characterizing the pharmacokinetic and pharmacodynamic profiles of XL880.
Michael Morrissey, executive vice president of discovery at Exelixis, said: "XL880 has demonstrated potent inhibition of MET and other critical drivers of cancer in preclinical studies.
In particular, preclinical experiments have shown that gastric cancer cell lines carrying amplifications of the MET gene are extremely sensitive to the growth inhibitory effects of XL880, providing a strong rationale for testing the clinical utility of the compound in this indication."
Source: Datamonitor
Related Articles
- ProUroCare Medical Completes Multiple Site Clinical Study for Imaging Prostate Abnormalities
- Ikonisys Reports Positive Results From Clinical Study Designed to Evaluate the Efficacy of Circulating Tumor Cell Detection With Ikonisys' Automated Microscope
- Idera Pharmaceuticals Announces Preliminary Data From Phase 2a Clinical Study of IMO-2055 Monotherapy in Renal Cell Carcinoma
- Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies With REOLYSIN(R)
- Epigenomics AG Demonstrates Feasibility of Convenient Blood Test for Lung Cancer Detection in Clinical Study
- Leading Cancer Centers Commence Clinical Study for Prostate Cancer Patients Receiving External Beam Radiation Therapy
- Australian Cancer Technology Provides Update on Ongoing Clinical Study of Pentrys Vaccine for Prostate Cancer
- Vertex and Merck Announce First Clinical Study for Aurora Kinase Inhibitor, VX-680, in Solid Tumor Cancers
- Bioaccelerate's Development Partner AustCancer Commences Phase II Clinical Study of RP101 for Metastatic Pancreatic Cancer
- AustCancer Commences Phase II Clinical Study of RP101 for Metastatic Pancreatic Cancer
 |
 |
User Comments (0)
RSS Feeds